ArticleDiscover oncology2025
High linc00473 expression indicated worse cancer prognosis, based on the meta-analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowing evidence reported that linc00473 was abnormally expressed in various tumor tissues, elevated linc00473 expression manifested unsatisfactory survival outcome. Due to the inconsistent results from different research, a meta-analysis was executed to examine the link between linc00473 level and cancer prognosis.
methodsAn exhaustive search was made from relative databases, suitable publications were enrolled based on the inclusion and exclusion criteria. The overall literature quality was assessed based on the Newcastle-Ottawa Scale (NOS) score. Relevant data was extracted such as overall survival (OS), TNM stage and lymph node metastasis (LNM) and so on. To determine the stability and dependability of the aggregated results, sensitivity analysis was implemented, while Begg's analysis was applied to examine possible publication bias.
resultsThis meta-analysis encompassed 15 publications totaling 1144 patients. Linc00473 showed elevation in most tumor tissues, with heightened linc00473 expression suggesting inferior cancer prognosis (HR: 1.850, 95% confidence interval (CI): 1.230-2.80, P = 0.003). Subgroup analysis findings revealed comparable negative prognostic implications in the respiratory system (HR: 2.23, 95%CI: 1.39-3.58, P = 0.0008), reproductive system (HR: 3.19, 95%CI: 2.00-5.11, P < 0.00001) and additional systems (HR: 2.56, 95%CI: 1.37-4.80, P = 0.003). Moreover, elevated linc00473 expression correlated with advanced TNM stage (OR: 3.78, 95%CI: 2.75-5.19, P < 0.00001), distant metastasis (OR: 4.61, 95%CI: 2.53-8.39, P < 0.00001), increased tumor size (OR: 3.10, 95%CI: 2.13-4.50, P < 0.00001) and poor histological grade (OR: 1.85, 95%CI: 1.29-2.67, P = 0.0009). Sensitivity analysis confirmed the overall results' stability and reliability, while Begg's analysis indicated no substantial publication bias existed among the examined publications.
conclusionHigh linc00473 expression has been detected across diverse tumor tissues, high linc00473 expression implies poor cancer prognosis, linc00473 potentially functions as a prospective therapeutic target and prognostic indicator. More high-quality documents were wished to implement to support the results of this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.